Evidence map›Paper›PMID 40025387›Full record

ArticleAdvances in therapy2025

Cardiovascular Risks and Survival with Abiraterone vs Enzalutamide in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer in Germany: AVENGER Study.

Axel S Merseburger, Eugen Dornstauder, Carsten-Henning Ohlmann, Armen Aprikian, Sophia Junker, Philipp Hahn, Andrew Chilelli, Matthias Stoelzel, Alexis Serikoff, Stefan G Spitzer

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Advances in therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Axel S MerseburgerDepartment of Urology, University Hospital Schleswig-Holstein, Lübeck, Germany. Axel.Merseburger@uksh.de.
Eugen DornstauderAstellas Pharma GmbH, Munich, Germany.
Carsten-Henning OhlmannDepartment of Urology, Johanniter Hospital Bonn, Bonn, Germany.
Armen AprikianDivision of Urology, Department of Surgery, McGill University, Montreal, Canada.
Sophia JunkerCytel Inc., Berlin, Germany.
Philipp HahnInstitute for Pharmacoeconomics and Medication Logistics (IPAM), Wismar, Germany.
Andrew ChilelliAstellas Pharma Europe, Addlestone, UK.
Matthias StoelzelAstellas Pharma B.V., Leiden, The Netherlands.
Alexis SerikoffAstellas Pharma Europe, Addlestone, UK.
Stefan G SpitzerPraxisklinik Herz und Gefäße Dresden, Akademische Lehrpraxisklinik der TU Dresden, Dresden, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionRecent real-world studies compared effectiveness and safety of enzalutamide (ENZA) and abiraterone acetate (AA) for metastatic castration-resistant prostate cancer (mCRPC). The growing evidence needs further substantiation with long-term data. This study, the first to use German data, investigated cardiovascular (CV) event risk and overall survival (OS) in patients initiating ENZA or AA. AA (2012) and ENZA (2014) are widely used for mCRPC in Germany.

methodsThis retrospective study used data of chemotherapy-naïve patients with mCRPC on ENZA or AA (2012-2020) from two German claims databases (AOK PLUS and GWQ ServicePlus). The primary endpoint was time to first CV event (CV-related hospitalization) analyzed via a meta-analysis of Cox proportional hazard models of propensity score-matched (PSM) intention-to-treat cohorts. Other endpoints were baseline characteristics, CV event rate, number of CV events per patient, and OS.

resultsOf 2240 patients in the total study population (ENZA, 828; AA, 1412), 796 PSM patients were included in each group. ENZA patients were older and had a higher prevalence of some comorbidities, but without meaningful differences after PSM. Further, 386 patients had ≥ 1 CV event (ENZA, 172; AA, 214). ENZA was associated with a significantly lower risk of CV events (hazard ratio [HR] 0.70, 95% confidence interval [CI] 0.57-0.86, p = 0.001, I

conclusionsThe unmatched ENZA cohort had higher average age and more comorbidities than the AA cohort, but no meaningful differences were noted after PSM. ENZA was associated with a significantly lower risk of CV events and improved OS.

Indexed as

Abiraterone AcetateAndrostenesAntineoplastic AgentsCardiovascular DiseasesPhenylthiohydantoinProstatic Neoplasms, Castration-ResistantAgedAged, 80 and overBenzamidesGermanyHumansMaleMiddle AgedNitrilesRetrospective StudiesabirateroneAbiraterone AcetateAndrostenesAntineoplastic AgentsBenzamidesenzalutamideNitrilesPhenylthiohydantoinAbirateroneCardiovascular eventsCastration-resistant prostate cancerEnzalutamideOverall survivalPropensity score matching

Identifiers

PMID40025387
PMCPMC11929622

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.